British Lung Foundation
13
0
1
10
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Low Risk
Score: 25/100
0.0%
0 terminated/withdrawn out of 13 trials
100.0%
+13.5% vs industry average
31%
4 trials in Phase 3/4
0%
0 of 10 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (13)
Niraparib Efficacy in Patient With Unresectable Mesothelioma
Role: collaborator
BPF Genetics of ILD Study
Role: collaborator
Mesothelioma Stratified Therapy (MiST) : A Multi-drug Phase II Trial in Malignant Mesothelioma
Role: collaborator
Early Pulmonary Rehabilitation Following Acute COPD Exacerbation
Role: collaborator
Physical Activity Following Pulmonary Rehabilitation in COPD
Role: collaborator
Computed Tomography Assessment of Regional Ventilation (CURVE)
Role: collaborator
Malignant Mesothelioma - Can we Improve Quality of Life
Role: collaborator
Isotoxic Intensity Modulated Radiotherapy (IMRT) in Stage III Non Small Cell Lung Cancer (NSCLC) - A Feasibility Study
Role: collaborator
The Use of Inflammatory Markers to Guide Therapy in Children With Severe Asthma
Role: collaborator
Metformin in Chronic Obstructive Pulmonary Disease
Role: collaborator
Launching an Asthma Initiative Designed to Improve Asthma Management and Outcomes
Role: collaborator
Trial of Adjunctive Vitamin D in Tuberculosis Treatment
Role: collaborator
Withdrawal of Inhaled Corticosteroids in Patients With COPD in Primary Care
Role: collaborator
All 13 trials loaded